Roche announces initiation of Phase III clinical trial of tocilizumab in hospitalised patients with severe COVID-19 pneumonia

This study is expected to begin enrolling as soon as possible in early April with a target of approximately 330 patients globally, including the US. Primary and secondary endpoints include clinical status, mortality, mechanical ventilation and ICU variables.